首页> 外文期刊>Allergy and asthma proceedings >The effect of intranasal carbon dioxide on the acute response to nasal challenge with allergen.
【24h】

The effect of intranasal carbon dioxide on the acute response to nasal challenge with allergen.

机译:鼻内二氧化碳对过敏原对鼻腔激发的急性反应的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

Intranasal carbon dioxide (CO(2)) was shown to reduce symptoms of seasonal allergic rhinitis (SAR). This study was designed to evaluate the effect of CO(2) on nasal allergen challenge. We conducted a randomized, controlled, crossover trial in 12 subjects with SAR outside their pollen season. Thirty minutes after a 20-second exposure to CO(2) or no exposure, subjects underwent a unilateral, localized, nasal allergen challenge. Filter paper disks were placed on the nasal septum to deliver a sham challenge followed by 2 increasing doses of either grass or ragweed allergen. Secretions were collected from both sides of the septum to evaluate the nasonasal reflex and were assayed for histamine. Nasal and eye symptoms were recorded. The primary outcome measure was the contralateral, reflex, secretory response to allergen as measured by secretion weights. Secondary outcome measures included ipsilateral nasal secretion weights, nasal and eye symptoms, levels of histamine in nasal secretions, and eosinophils in nasal scrapings. Subjects reported a transient burning sensation during exposure to CO(2). Compared with no treatment, active treatment resulted in a significant reduction in sneezes (p = 0.05), contralateral secretion weights (p = 0.04), and bilateral runny nose symptoms (p = 0.01). Ipsilateral secretion weights were numerically reduced. Histamine levels in ipsilateral nasal secretions increased significantly when the subjects received sham treatment but did not increase after pretreatment with CO(2). Treatment with nasal CO(2) resulted in partial reduction of the acute response to allergen challenge. Reflex responses were reduced, supporting an effect on neuronal mechanisms, which predict usefulness in the treatment of allergic rhinitis. Registered with the U.S. National Institutes of Health clinicaltrials.gov. Identifier: NCT00618410.
机译:鼻内二氧化碳(CO(2))被证明可以减少季节性过敏性鼻炎(SAR)的症状。这项研究旨在评估CO(2)对鼻过敏原挑战的影响。我们对12个花粉季节以外的SAR受试者进行了一项随机,对照,交叉试验。暴露于CO(2)20秒或未暴露20秒后的30分钟,受试者经历了单侧,局部,鼻部过敏原攻击。将滤纸盘放在鼻中隔上以进行假刺激,然后再增加2剂量的草或豚草过敏原。从隔膜的两侧收集分泌物以评估鼻沟反射,并分析组胺。记录鼻和眼症状。主要的结局指标是对对过敏原的对侧,反射性,分泌性反应,以分泌物重量衡量。次要结果指标包括同侧鼻分泌物重量,鼻和眼症状,鼻分泌物中的组胺水平以及鼻scrap中的嗜酸性粒细胞。受试者报告在暴露于CO(2)的过程中有短暂的灼烧感。与不治疗相比,积极治疗可显着减少打喷嚏(p = 0.05),对侧分泌物重量(p = 0.04)和双侧流鼻涕症状(p = 0.01)。同侧分泌物重量减少。当受试者接受假治疗时,同侧鼻分泌物中的组胺水平显着增加,但在用CO(2)预处理后并未增加。鼻CO(2)的治疗导致对过敏原激发的急性反应的部分降低。反射反应减少,支持对神经元机制的影响,这预测了在过敏性鼻炎的治疗中的有用性。已在美国国立卫生研究院Clinicaltrials.gov注册。标识符:NCT00618410。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号